These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 35350193)

  • 1. Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant.
    Campos GRF; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; de Assis JV; de Souza Silva TB; Alves PA; da Rocha Fernandes G; de Oliveira JG; Rahal P; Queiroz RFG; Nogueira ML
    medRxiv; 2022 Mar; ():. PubMed ID: 35350193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant.
    Campos GRF; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; de Assis JV; de Souza Silva TB; Alves PA; da Rocha Fernandes G; de Oliveira JG; Rahal P; Grenfell RFQ; Nogueira ML
    Commun Med (Lond); 2022; 2():76. PubMed ID: 35784447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
    Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
    Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol.
    Campos GRF; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; de Assis JV; Silva TBS; Alves PA; Fernandes GDR; de Oliveira JG; Rahal P; Grenfell RFQ; Nogueira ML
    Front Cell Infect Microbiol; 2024; 14():1371695. PubMed ID: 38638823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine.
    Liwsrisakun C; Pata S; Laopajon W; Takheaw N; Chaiwong W; Inchai J; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Chuensirikulchai K; Kasinrerk W
    Immun Ageing; 2022 May; 19(1):24. PubMed ID: 35610643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.
    Khong KW; Liu D; Leung KY; Lu L; Lam HY; Chen L; Chan PC; Lam HM; Xie X; Zhang R; Fan Y; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody.
    Lai KT; Lai Wan Loong EY; Fung TL; Luk LW; Lau CC; Zee JS; Ma ES; Tang BS
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster.
    Chantasrisawad N; Puthanakit T; Kornsitthikul K; Jaru-Ampornpan P; Tawan M; Matapituk P; Sophonphan J; Anugulruengkitt S; Tangsathapornpong A; Katanyutanon A;
    Vaccine X; 2022 Dec; 12():100221. PubMed ID: 36213592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents.
    Assavavongwaikit P; Chantasrisawad N; Himananto O; Phasomsap C; Klawaja P; Cartledge S; Nadsasarn R; Jupimai T; Kawichai S; Anugulruengkitt S; Puthanakit T; On Behalf Of The Study Team
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses.
    Zhang L; Chen H; Yang S; Zhao Y; Shen X; He X; Ye H; Wang D; Lou J; Wang Y; Wu S
    Front Immunol; 2022; 13():990071. PubMed ID: 36203574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of COVID-19 Vaccination on Healthcare Worker Infection Rate and Outcome during SARS-CoV-2 Omicron Variant Outbreak in Hong Kong.
    Zee ST; Kwok LF; Kee KM; Fung LH; Luk WP; Chan TL; Leung CP; Yu PW; Hung J; SzeTo KY; Chan WL; Tang SF; Lin WC; Ma SK; Lee KH; Lau CC; Yung WH
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine.
    Goh YS; Fong SW; Rouers A; Chang ZW; Tay MZ; Chavatte JM; Zhuo NZ; Hor PX; Loh CY; Huang Y; Wong JXE; Tan YJ; Lim DRX; Wang B; Ngoh EZX; Salleh SNM; Lee RTC; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; ; ; Maurer-Stroh S; Wang CI; Leo YS; Lin RT; Ren EC; Lye DC; Young BE; Lim PL; Ng LF; Renia L
    Clin Transl Immunology; 2022; 11(8):e1403. PubMed ID: 36016852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels and durability of neutralizing antibodies against SARS-CoV-2 Omicron and other variants after ChAdOx-1 or BNT162b2 booster in CoronaVac-primed elderly individuals.
    Takheaw N; Liwsrisakun C; Laopajon W; Pata S; Chaiwong W; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
    Heliyon; 2023 Apr; 9(4):e15653. PubMed ID: 37095993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant.
    Zhou Z; Du P; Li N; Xiong X; Tang S; Dai Q; Wang T; Yu M; Man M; Lam K; Baptista-Hon DT; Tai WH; Monteiro O; Ng WS; Lee UM; Liu Z; Zhang K; Li G
    MedComm (2020); 2022 Jun; 3(2):e143. PubMed ID: 35592756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern.
    Schultz BM; Melo-González F; Duarte LF; Gálvez NM; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Vallejos OP; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo M; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
    medRxiv; 2022 Feb; ():. PubMed ID: 35441179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination.
    Li J; Li X; Wang E; Yang J; Li J; Huang C; Zhang Y; Chen K
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
    Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
    J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.